The Latest Breaking News from Pfizer

Over 1 million courses of Paxlovid prescribed in one month for first time

There were 1.26 million courses dispensed last month, a 37% increase when compared to June numbers.

Axios · Aug 4, 2022

Check Out What Whales Are Doing With PFE

Someone with a lot of money to spend has taken a bullish stance on Pfizer (NYSE:PFE). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga · Aug 3, 2022

How common is Paxlovid rebound as Biden tests positive again for Covid?

Paxlovid good at stopping hospitalisation for high-risk groups, despite occasional rebound

The Independent UK · Aug 3, 2022

Lisa Jarvis: At last, a simple strategy for COVID booster shots

The Food and Drug Administration reportedly has a new strategy for rolling out new booster shots that should bring needed clarity to COVID vaccination in the U.S. Going forward, most Americans will get the same advice about when to get their next shots.

Tribune News Service · Aug 2, 2022

How common is Paxlovid rebound as Biden tests positive again for Covid?

Paxlovid good at stopping hospitalisation for high-risk groups, despite occasional rebound

The Independent UK · Aug 1, 2022

The kids are all right: Fewer COVID-19 vaccine side effects

Australian children aged 5–15 years have reported fewer side effects in the days after receiving the mRNA COVID-19 vaccine than those in clinical trials.

The New Daily · Jul 31, 2022

Biden tests positive for COVID-19 again, returns to isolation

White House physician Dr. Kevin O’Connor said in a letter that Biden “has experienced no reemergence of symptoms, and continues to feel quite well.”

Chicago Sun-Times · Jul 30, 2022

Andrew Hopkins of Exscientia: the man using AI to cure disease

The British scientist’s company employs artificial intelligence to drastically cut the time of drug development

The Guardian - UK · Jul 30, 2022

Recap Of Friday's Biotech Catalysts - End of The Day Summary

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older. The company expects commercial launch of the product in Mid-August. Arcutis shares traded in a range of…

Benzinga · Jul 29, 2022

Zenara Pharma gets CDSCO nod to make copy of Pfizer’s Paxlovid

Combi pack of Nirmatrelvir, Ritonavir tablets is for patients with moderate symptoms of Covid-19

The Hindu · Jul 28, 2022